[The treatment of neurospastic vascular diseases in Raynaud phenomenon].
The efficacy of proposed methods for cardiovascular diseases with Raynaud phenomenon manifestations treatment was estimated. After application of the author method the patients extremities temperature had raised by 2 .50 degreesC. They had noted the pain and the extremities oedema elimination, trophic ulcers healing. According to Doppler investigation data the blood flow linear speed increase by 30 0% in comparison with pretreatment one was noted. The posttreatment complications were absent. Fair and good results were observed in 306 (82.3%) patients, in 21 (5.6%) patients the treatment was repeated in conditions of severe ischemia and the blood flow decompensation present. In 14 (3.8%) patients a high epidural blockade of sympathic nodes in portion of high thoracic and lower cervical vertebra according to the author method was performed. In far-remote period (in 3-10 years) the positive effect was prolonged in 298 (80.1%) patients.
Buryĭ
V T
VT
Buryĭ
V V
VV
D001341:Autonomic Nervous System / Q000502:physiology; D002318:Cardiovascular Diseases / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D004599:Electric Stimulation Therapy / Q000379:methods*; D005260:Female; D005528:Foot / Q000098:blood supply / Q000294:innervation; D006225:Hand / Q000098:blood supply / Q000294:innervation; D006801:Humans; D008297:Male; D011827:Radiation; D011928:Raynaud Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D012039:Regional Blood Flow / Q000187:drug effects; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D014665:Vasodilator Agents